Symbols / CGEM Stock $12.95 -6.43% Cullinan Therapeutics, Inc.
CGEM (Stock) Chart
About
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Stock Fundamentals
Scroll to Statements| Market Cap | 783.81M | Enterprise Value | 462.47M | Income | -219.88M | Sales | — | Book/sh | 6.79 | Cash/sh | 6.24 |
| Dividend Yield | — | Payout | 0.00% | Employees | 109 | IPO | — | P/E | — | Forward P/E | -4.50 |
| PEG | — | P/S | — | P/B | 1.91 | P/C | — | EV/EBITDA | -1.92 | EV/Sales | — |
| Quick Ratio | 10.09 | Current Ratio | 10.25 | Debt/Eq | 0.66 | LT Debt/Eq | — | EPS (ttm) | -3.36 | EPS next Y | -2.88 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-07 | ROA | -28.23% | ROE | -44.02% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 60.53M | Shs Float | 43.21M | Short Float | 15.98% |
| Short Ratio | 9.79 | Short Interest | — | 52W High | 16.74 | 52W Low | 5.68 | Beta | -0.11 | Avg Volume | 794.11K |
| Volume | 523.34K | Target Price | $31.35 | Recom | None | Prev Close | $13.84 | Price | $12.95 | Change | -6.43% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Wedbush | Outperform → Outperform | $36 |
| 2026-02-17 | init | Citigroup | — → Buy | $33 |
| 2026-02-02 | init | Guggenheim | — → Buy | $30 |
| 2026-01-08 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-12-09 | main | Wedbush | Outperform → Outperform | $34 |
| 2025-11-20 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-09-10 | reit | BTIG | Buy → Buy | $32 |
| 2025-08-18 | main | Morgan Stanley | Overweight → Overweight | $28 |
| 2025-05-12 | main | UBS | Buy → Buy | $24 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-02-28 | main | Stifel | Buy → Buy | $19 |
| 2024-10-24 | init | UBS | — → Buy | $30 |
| 2024-08-09 | reit | Wedbush | Outperform → Outperform | $36 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-05-16 | main | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-05-16 | reit | Wedbush | Outperform → Outperform | $36 |
| 2024-05-01 | init | Stifel | — → Buy | $40 |
- We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash Wisely - simplywall.st hu, 23 Apr 2026 10
- Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus Sun, 19 Apr 2026 22
- $CGEM stock is up 14% today. Here's what we see in our data. - Quiver Quantitative Fri, 31 Oct 2025 07
- Trading Systems Reacting to (CGEM) Volatility - Stock Traders Daily Mon, 20 Apr 2026 03
- Is Cullinan (CGEM) stock showing weakness (+2.17%) 2026-04-18 - Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai Sat, 18 Apr 2026 10
- Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 6.3% - What's Next? - MarketBeat Mon, 06 Apr 2026 07
- Vanguard disaggregates holdings; reports 0 shares of Cullinan Therapeutics (CGEM) - Stock Titan hu, 26 Mar 2026 07
- Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Yahoo Finance Mon, 15 Dec 2025 08
- Is Cullinan (CGEM) Stock better than industry peers | Price at $14.47, Down 2.62% - Breakout Signals - Cổng thông tin điện tử Tỉnh Sơn La Wed, 08 Apr 2026 07
- Will Cullinan (CGEM) Stock Grow in 2026 | Price at $15.45, Up 7.07% - Stock Surge - UBND thành phố Hải Phòng Mon, 06 Apr 2026 07
- Cullinan Therapeutics: Worthy Of A Small Position - Seeking Alpha Fri, 17 Oct 2025 07
- $CGEM stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 08 Dec 2025 08
- CGEM SEC Filings - Cullinan Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 03
- Is Cullinan (CGEM) Stock priced for growth | Price at $14.49, Down 0.31% - Sell Signals - Xã Thanh Hà Mon, 13 Apr 2026 07
- Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength - Yahoo Finance Fri, 23 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
241.65
+22.71%
|
196.92
+3.29%
|
190.65
+44.28%
|
132.14
|
| Research And Development |
|
187.40
+31.14%
|
142.90
-3.55%
|
148.16
+61.13%
|
91.95
|
| Selling General And Administration |
|
54.25
+0.43%
|
54.02
+27.12%
|
42.49
+5.73%
|
40.19
|
| General And Administrative Expense |
|
54.25
+0.43%
|
54.02
+27.12%
|
42.49
+5.73%
|
40.19
|
| Other Gand A |
|
54.25
+0.43%
|
54.02
+27.12%
|
42.49
+5.73%
|
40.19
|
| Total Expenses |
|
241.65
+22.71%
|
196.92
+3.29%
|
190.65
+44.28%
|
132.14
|
| Operating Income |
|
-241.65
-22.71%
|
-196.92
-3.29%
|
-190.65
-44.28%
|
-132.14
|
| Total Operating Income As Reported |
|
-241.65
-22.71%
|
-196.92
-3.05%
|
-191.09
-232.11%
|
144.65
|
| EBITDA |
|
-241.34
-22.75%
|
-196.61
-3.30%
|
-190.34
-44.15%
|
-132.04
|
| Normalized EBITDA |
|
-241.34
-22.75%
|
-196.61
-3.54%
|
-189.90
+53.55%
|
-408.83
|
| Reconciled Depreciation |
|
0.31
+1.63%
|
0.31
-1.29%
|
0.31
+233.33%
|
0.09
|
| EBIT |
|
-241.65
-22.71%
|
-196.92
-3.29%
|
-190.65
-44.28%
|
-132.14
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-0.44
-100.16%
|
276.79
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-0.44
-100.16%
|
276.79
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.44
-100.16%
|
276.79
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
0.44
|
0.00
|
| Net Income |
|
-219.88
-31.36%
|
-167.38
-9.28%
|
-153.16
-237.72%
|
111.21
|
| Pretax Income |
|
-219.88
-31.30%
|
-167.46
+1.04%
|
-169.22
-211.83%
|
151.32
|
| Net Non Operating Interest Income Expense |
|
22.21
-25.11%
|
29.66
+37.14%
|
21.63
+227.14%
|
6.61
|
| Net Interest Income |
|
22.21
-25.11%
|
29.66
+37.14%
|
21.63
+227.14%
|
6.61
|
| Interest Income Non Operating |
|
22.21
-25.11%
|
29.66
+37.14%
|
21.63
+227.14%
|
6.61
|
| Interest Income |
|
22.21
-25.11%
|
29.66
+37.14%
|
21.63
+227.14%
|
6.61
|
| Other Income Expense |
|
-0.44
-122.61%
|
-0.20
+1.00%
|
-0.20
-100.07%
|
276.84
|
| Other Non Operating Income Expenses |
|
-0.44
-122.61%
|
-0.20
-183.26%
|
0.24
+319.30%
|
0.06
|
| Gain On Sale Of Business |
|
—
|
—
|
0.00
-100.00%
|
276.79
|
| Tax Provision |
|
0.00
-100.00%
|
0.12
+100.83%
|
-14.12
-133.53%
|
42.12
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+151.50%
|
0.00
-69.97%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-0.04
-100.05%
|
76.97
|
| Net Income Including Noncontrolling Interests |
|
-219.88
-31.21%
|
-167.57
-8.04%
|
-155.10
-242.04%
|
109.19
|
| Net Income From Continuing Operation Net Minority Interest |
|
-219.88
-31.36%
|
-167.38
-9.28%
|
-153.16
-237.72%
|
111.21
|
| Net Income From Continuing And Discontinued Operation |
|
-219.88
-31.36%
|
-167.38
-9.28%
|
-153.16
-237.72%
|
111.21
|
| Net Income Continuous Operations |
|
-219.88
-31.21%
|
-167.57
-8.04%
|
-155.10
-242.04%
|
109.19
|
| Minority Interests |
|
0.00
-100.00%
|
0.19
-90.10%
|
1.94
-3.96%
|
2.02
|
| Normalized Income |
|
-219.88
-31.36%
|
-167.38
-9.57%
|
-152.76
-72.42%
|
-88.60
|
| Net Income Common Stockholders |
|
-219.88
-31.36%
|
-167.38
-9.28%
|
-153.16
-237.72%
|
111.21
|
| Diluted EPS |
|
—
|
-2.78
+13.40%
|
-3.21
-234.87%
|
2.38
|
| Basic EPS |
|
—
|
-2.78
+13.40%
|
-3.21
-230.49%
|
2.46
|
| Basic Average Shares |
|
—
|
53.77
+29.41%
|
41.55
-8.00%
|
45.16
|
| Diluted Average Shares |
|
—
|
53.77
+29.41%
|
41.55
-10.91%
|
46.64
|
| Diluted NI Availto Com Stockholders |
|
-219.88
-31.36%
|
-167.38
-9.28%
|
-153.16
-237.72%
|
111.21
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
448.37
-27.89%
|
621.82
+28.43%
|
484.18
-13.71%
|
561.12
|
| Current Assets |
|
386.76
-6.73%
|
414.67
-13.65%
|
480.19
+1.21%
|
474.47
|
| Cash Cash Equivalents And Short Term Investments |
|
377.90
-5.28%
|
398.98
-14.58%
|
467.07
-0.05%
|
467.29
|
| Cash And Cash Equivalents |
|
88.33
+6.42%
|
83.00
-15.67%
|
98.43
-36.96%
|
156.15
|
| Cash Equivalents |
|
—
|
—
|
—
|
—
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Other Short Term Investments |
|
289.56
-8.36%
|
315.97
-14.29%
|
368.63
+18.48%
|
311.14
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
8.86
-43.53%
|
15.69
+19.56%
|
13.12
+82.79%
|
7.18
|
| Total Non Current Assets |
|
61.62
-70.26%
|
207.16
+5090.58%
|
3.99
-95.39%
|
86.64
|
| Net PPE |
|
3.05
+29.83%
|
2.35
-33.47%
|
3.53
-33.41%
|
5.30
|
| Gross PPE |
|
4.02
+33.64%
|
3.01
-22.55%
|
3.88
-28.59%
|
5.44
|
| Accumulated Depreciation |
|
-0.97
-47.26%
|
-0.66
-86.93%
|
-0.35
-160.74%
|
-0.14
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.81
+6.41%
|
0.77
+0.00%
|
0.77
+12.33%
|
0.68
|
| Other Properties |
|
2.63
+57.77%
|
1.67
-34.45%
|
2.54
-38.43%
|
4.13
|
| Leases |
|
0.58
+0.00%
|
0.58
+0.00%
|
0.58
-8.28%
|
0.63
|
| Investments And Advances |
|
58.27
-71.50%
|
204.44
|
0.00
-100.00%
|
80.88
|
| Other Non Current Assets |
|
0.30
-18.85%
|
0.37
-20.26%
|
0.46
+0.00%
|
0.46
|
| Total Liabilities Net Minority Interest |
|
39.64
+25.87%
|
31.50
+3.99%
|
30.29
+16.10%
|
26.09
|
| Current Liabilities |
|
37.74
+23.15%
|
30.65
+8.92%
|
28.14
+25.06%
|
22.50
|
| Payables And Accrued Expenses |
|
26.01
+44.73%
|
17.97
-4.38%
|
18.80
+30.27%
|
14.43
|
| Payables |
|
9.62
+25.39%
|
7.68
-25.92%
|
10.36
+49.27%
|
6.94
|
| Accounts Payable |
|
0.84
-50.00%
|
1.68
-32.53%
|
2.49
-6.28%
|
2.66
|
| Other Payable |
|
8.78
+46.55%
|
5.99
-23.83%
|
7.87
|
—
|
| Current Accrued Expenses |
|
16.39
+59.15%
|
10.30
+22.09%
|
8.43
+12.66%
|
7.49
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
9.95
+0.17%
|
9.94
+42.19%
|
6.99
+54.72%
|
4.52
|
| Total Tax Payable |
|
—
|
—
|
0.00
-100.00%
|
4.28
|
| Income Tax Payable |
|
—
|
—
|
0.00
-100.00%
|
4.28
|
| Current Debt And Capital Lease Obligation |
|
0.78
-40.09%
|
1.30
-9.58%
|
1.44
-9.94%
|
1.60
|
| Current Debt |
|
—
|
—
|
—
|
0.18
|
| Other Current Borrowings |
|
—
|
—
|
—
|
0.18
|
| Current Capital Lease Obligation |
|
0.78
-40.09%
|
1.30
-9.58%
|
1.44
+1.34%
|
1.42
|
| Other Current Liabilities |
|
1.00
-30.69%
|
1.44
+57.22%
|
0.91
-53.25%
|
1.96
|
| Total Non Current Liabilities Net Minority Interest |
|
1.90
+124.15%
|
0.85
-60.51%
|
2.15
-40.11%
|
3.59
|
| Long Term Debt And Capital Lease Obligation |
|
1.90
+124.15%
|
0.85
-60.51%
|
2.15
-40.11%
|
3.59
|
| Long Term Capital Lease Obligation |
|
1.90
+124.15%
|
0.85
-60.51%
|
2.15
-40.11%
|
3.59
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
0.00
|
| Stockholders Equity |
|
408.73
-30.76%
|
590.33
+30.11%
|
453.70
-15.20%
|
535.03
|
| Common Stock Equity |
|
408.73
-30.76%
|
590.33
+30.11%
|
453.70
-15.20%
|
535.03
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+50.00%
|
0.00
-20.00%
|
0.01
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+50.00%
|
0.00
-20.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
60.24
+2.96%
|
58.51
+36.39%
|
42.90
-6.32%
|
45.80
|
| Ordinary Shares Number |
|
60.24
+2.96%
|
58.51
+36.39%
|
42.90
-6.32%
|
45.80
|
| Additional Paid In Capital |
|
995.82
+3.87%
|
958.70
+46.44%
|
654.68
+11.85%
|
585.32
|
| Retained Earnings |
|
-588.12
-59.71%
|
-368.24
-83.33%
|
-200.86
-321.13%
|
-47.70
|
| Gains Losses Not Affecting Retained Earnings |
|
1.02
+866.92%
|
-0.13
-3.10%
|
-0.13
+95.04%
|
-2.60
|
| Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.19
|
0.00
|
| Other Equity Adjustments |
|
1.02
+866.92%
|
-0.13
-3.10%
|
-0.13
+95.04%
|
-2.60
|
| Total Equity Gross Minority Interest |
|
408.73
-30.76%
|
590.33
+30.06%
|
453.89
-15.16%
|
535.03
|
| Total Capitalization |
|
408.73
-30.76%
|
590.33
+30.11%
|
453.70
-15.20%
|
535.03
|
| Working Capital |
|
349.01
-9.12%
|
384.02
-15.05%
|
452.05
+0.02%
|
451.97
|
| Invested Capital |
|
408.73
-30.76%
|
590.33
+30.11%
|
453.70
-15.23%
|
535.21
|
| Total Debt |
|
2.68
+24.73%
|
2.15
-40.08%
|
3.59
-30.82%
|
5.19
|
| Capital Lease Obligations |
|
2.68
+24.73%
|
2.15
-40.08%
|
3.59
-28.36%
|
5.01
|
| Net Tangible Assets |
|
408.73
-30.76%
|
590.33
+30.11%
|
453.70
-15.20%
|
535.03
|
| Tangible Book Value |
|
408.73
-30.76%
|
590.33
+30.11%
|
453.70
-15.20%
|
535.03
|
| Held To Maturity Securities |
|
58.27
-71.50%
|
204.44
|
0.00
-100.00%
|
80.88
|
| Investmentin Financial Assets |
|
58.27
-71.50%
|
204.44
|
0.00
-100.00%
|
80.88
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-175.75
-20.95%
|
-145.30
-8.21%
|
-134.28
-6.01%
|
-126.66
|
| Cash Flow From Continuing Operating Activities |
|
-175.75
-20.95%
|
-145.30
-8.21%
|
-134.28
-6.01%
|
-126.66
|
| Net Income From Continuing Operations |
|
-219.88
-31.21%
|
-167.57
-8.04%
|
-155.10
-242.04%
|
109.19
|
| Depreciation Amortization Depletion |
|
0.31
+1.63%
|
0.31
-1.29%
|
0.31
+233.33%
|
0.09
|
| Depreciation And Amortization |
|
0.31
+1.63%
|
0.31
-1.29%
|
0.31
+233.33%
|
0.09
|
| Other Non Cash Items |
|
—
|
—
|
0.13
-64.97%
|
0.37
|
| Stock Based Compensation |
|
36.04
-4.72%
|
37.82
+24.27%
|
30.44
+8.87%
|
27.96
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
0.44
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-276.75
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
0.11
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-0.08
|
| Change In Working Capital |
|
14.08
+3720.57%
|
-0.39
-14.75%
|
-0.34
-103.03%
|
11.18
|
| Change In Prepaid Assets |
|
6.90
+379.00%
|
-2.47
+58.41%
|
-5.94
-426.02%
|
-1.13
|
| Change In Payables And Accrued Expense |
|
7.19
+245.03%
|
2.08
-62.84%
|
5.61
-54.45%
|
12.31
|
| Change In Accrued Expense |
|
8.03
+177.24%
|
2.90
-71.21%
|
10.05
+17.82%
|
8.53
|
| Change In Payable |
|
-0.84
-3.33%
|
-0.81
+81.75%
|
-4.45
-217.92%
|
3.77
|
| Change In Account Payable |
|
-0.84
-3.33%
|
-0.81
-386.23%
|
-0.17
+67.19%
|
-0.51
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
179.99
+232.04%
|
-136.31
-480.70%
|
35.81
-85.62%
|
248.97
|
| Cash Flow From Continuing Investing Activities |
|
179.99
+232.04%
|
-136.31
-480.70%
|
35.81
-85.62%
|
248.97
|
| Net PPE Purchase And Sale |
|
-0.05
|
0.00
+100.00%
|
-0.21
+80.04%
|
-1.04
|
| Purchase Of PPE |
|
-0.05
|
0.00
+100.00%
|
-0.21
+81.64%
|
-1.13
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.09
|
| Capital Expenditure |
|
-0.05
|
—
|
-0.21
+81.64%
|
-1.13
|
| Net Investment Purchase And Sale |
|
180.04
+232.08%
|
-136.31
-478.50%
|
36.01
+244.15%
|
-24.98
|
| Purchase Of Investment |
|
-236.53
+67.20%
|
-721.13
-93.13%
|
-373.38
+1.20%
|
-377.92
|
| Sale Of Investment |
|
416.57
-28.77%
|
584.82
+42.85%
|
409.40
+16.00%
|
352.93
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
-100.00%
|
275.00
|
| Gain Loss On Sale Of Business |
|
—
|
—
|
0.00
+100.00%
|
-276.79
|
| Financing Cash Flow |
|
1.09
-99.59%
|
266.19
+553.21%
|
40.75
+257.14%
|
-25.93
|
| Cash Flow From Continuing Financing Activities |
|
1.09
-99.59%
|
266.19
+553.21%
|
40.75
+257.14%
|
-25.93
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
1.82
+942.86%
|
0.17
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
1.82
-23.16%
|
2.38
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-2.20
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.82
-23.16%
|
2.38
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-2.20
|
| Net Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.82
+942.86%
|
0.17
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
262.65
+584.20%
|
38.39
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.09
-86.37%
|
7.98
+1384.01%
|
0.54
-91.06%
|
6.02
|
| Net Other Financing Charges |
|
—
|
-4.45
|
—
|
-32.13
|
| Changes In Cash |
|
5.33
+134.53%
|
-15.43
+73.27%
|
-57.72
-159.89%
|
96.38
|
| Beginning Cash Position |
|
83.00
-15.67%
|
98.43
-36.96%
|
156.15
+161.24%
|
59.77
|
| End Cash Position |
|
88.33
+6.42%
|
83.00
-15.67%
|
98.43
-36.96%
|
156.15
|
| Free Cash Flow |
|
-175.80
-20.99%
|
-145.30
-8.05%
|
-134.48
-5.23%
|
-127.80
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.03
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
37.80
|
| Amortization Of Securities |
|
-6.31
+59.23%
|
-15.47
-52.34%
|
-10.15
-884.70%
|
1.29
|
| Change In Income Tax Payable |
|
—
|
0.00
+100.00%
|
-4.28
-200.00%
|
4.28
|
| Change In Tax Payable |
|
—
|
0.00
+100.00%
|
-4.28
-200.00%
|
4.28
|
| Common Stock Issuance |
|
0.00
-100.00%
|
262.65
+584.20%
|
38.39
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
262.65
+584.20%
|
38.39
|
0.00
|
| Sale Of Business |
|
—
|
—
|
0.00
-100.00%
|
275.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-10 View
- 8-K2026-03-10 View
- 42026-03-09 View
- 42026-02-26 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-23 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|